Placental Growth and Adverse Pregnancy Outcomes
|ClinicalTrials.gov Identifier: NCT01669525|
Recruitment Status : Completed
First Posted : August 21, 2012
Last Update Posted : July 18, 2017
|Condition or disease|
|Hypertension Induced by Pregnancy Pre-Eclampsia IUGR|
|Study Type :||Observational|
|Actual Enrollment :||1043 participants|
|Official Title:||Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
- Small for gestational birth weight (SGA-dichotomous) [ Time Frame: from 11-14 weeks in pregnancy until delivery (approximately 40 weeks) ]Neonatal weight and length are recorded at birth. This information will be retrieved from the medical record post partum.
- Includes a composite adverse outcome defined by any of the following: SGA, pre-eclampsia, or perinatal death. [ Time Frame: post partum ]Information about pregnancy outcomes will be retrieved from the maternal and neonatal medical record post partum.
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01669525
|United States, Pennsylvania|
|University of Pennsylvania Health System|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Nadav Schwartz, MD||University of Pennsylvania|